JENNIFER CALLARD: Open Payments
NPI 1437547106 · GEORGETOWN, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,289 in 107 payments from 24 companies in 2025. Trend: 2023 $1,998 · 2024 $2,785 · 2025 $2,289
Food & beverage: $2,289
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $320 |
| PFIZER INC. | 14 | $259 |
| Lilly USA, LLC | 7 | $248 |
| Corcept Therapeutics | 7 | $240 |
| Novo Nordisk Inc | 10 | $195 |
| GlaxoSmithKline, LLC. | 10 | $177 |
| AstraZeneca Pharmaceuticals LP | 6 | $116 |
| Sumitomo Pharma America, Inc. | 6 | $98 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $73 |
| Novartis Pharmaceuticals Corporation | 3 | $63 |
Products named: Korlym, JARDIANCE, TRELEGY ELLIPTA, ZEPBOUND, UBRELVY, VRAYLAR, Ozempic, GEMTESA.
Industry payments across DE — which companies pay providers there.
